JNM -- Valkema et al. 46 (1 Supplement): 83S Figure 2

Click on image to view larger version.

FIGURE 2. Comparison of decline in CLR in 28 patients treated with ⁹⁰Y-DOTATOC (A) and 37 patients treated with ¹⁷⁷Lu-DOTATATE (B). Especially with ¹⁷⁷Lu-DOTATATE, most patients have CLR loss <5%/y (normal age-related CLR loss is 1%/y). Only patients with CLR loss >25%/y are expected to develop ESRD within 5 y.